Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
SM Jones, SH Sicherer, AW Burks, DYM Leung… - Journal of Allergy and …, 2017 - Elsevier
Background Peanut allergy is common, life-threatening, and without therapeutic options. We
evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut
allergy treatment. Objective We sought to evaluate the clinical, safety, and immunologic
effects of EPIT for the treatment of peanut allergy. Methods In this multicenter, double-blind,
randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25áyears)
were treated with placebo (ná= á25), Viaskin Peanut 100áμg (VP100; ná= á24) or Viaskin …
evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut
allergy treatment. Objective We sought to evaluate the clinical, safety, and immunologic
effects of EPIT for the treatment of peanut allergy. Methods In this multicenter, double-blind,
randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25áyears)
were treated with placebo (ná= á25), Viaskin Peanut 100áμg (VP100; ná= á24) or Viaskin …